Supplemental Figures 1 - 8 from Transgenic Expression of IL15 Improves Antiglioma Activity of IL13Rα2-CAR T Cells but Results in Antigen Loss Variants
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Figure 1: IL13Rα2-CAR and/or IL15 expression does not change T-cell phenotype. Supplementary Figure 2: Cell surface expression of IL13Rα2. Supplementary Figure 3: IL15 improves cell viability in the absence of exogenous cytokines. Supplementary Figure 4: Transgene expression is upregulated upon T cell activation. Supplemental Figure 5: IL13Rα2-CAR.IL15 T cells display activation-dependent IL15 production and greater proliferative capacity. Supplementary Figure 6: CID induces cell death in T cells genetically modified with retroviral vector encoding iC9.dNFGR.IL15. Supplemental Figure 7: Addition of exogenous IL15 increases CAR T-cell expansion in vitro. Supplementary Figure 8: IL13Rα2 or HER2 antigen loss variants are not killed by IL13Rα2- or HER2-CAR T cells.
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362551782